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Abstract
CD5 is a lymphoid-specific transmembrane glycoprotein constitutively expressed on thymocytes and mature T and B1a
lymphocytes. Current data support the view that CD5 is a negative regulator of antigen-specific receptor-mediated
signaling in these cells, and that this would likely be achieved through interaction with CD5 ligand/s (CD5L) of still
undefined nature expressed on immune or accessory cells. To determine the functional consequence of loss of CD5/CD5L
interaction in vivo, a new transgenic mouse line was generated (shCD5EmTg), expressing a circulating soluble form of human
CD5 (shCD5) as a decoy to impair membrane-bound CD5 function. These shCD5EmTg mice showed an enhanced response
to autologous antigens, as deduced from the presentation of more severe forms of experimentally inducible autoimmune
disease (collagen-induced arthritis, CIA; and experimental autoimmune encephalitis, EAE), as well as an increased anti-
tumoral response in non-orthotopic cancer models (B16 melanoma). This enhancement of the immune response was in
agreement with the finding of significantly reduced proportions of spleen and lymph node Treg cells (CD4+CD25+FoxP3+),
and of peritoneal IL-10-producing and CD5+ B cells, as well as an increased proportion of spleen NKT cells in shCD5EmTg
mice. Similar changes in lymphocyte subpopulations were observed in wild-type mice following repeated administration of
exogenous recombinant shCD5 protein. These data reveal the relevant role played by CD5/CD5L interactions on the
homeostasis of some functionally relevant lymphocyte subpopulations and the modulation of immune responses to
autologous antigens.
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Introduction
CD5 is a monomeric 67-kDa lymphocyte surface glycoprotein
belonging to the scavenger receptor cysteine-rich superfamily
(SRCR-SF) [1,2]. This ancient and well conserved group of
receptors includes both membrane-bound and/or secreted pro-
teins involved in the development and the regulation of innate and
specific immune responses [3,4]. CD5 is expressed on thymocytes
from early stages of their development, as well as on all mature
peripheral T lymphocytes, and a subpopulation of peripheral B
lymphocytes called B1a [5], with the highest expression levels
found on T and B cells subsets with well-known regulatory/
suppressor function (CD4+CD25+FoxP3+ Treg cells, and
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CD19+CD1d+IL-10+ Breg cells) [6–8]. On the surface of all these
lymphoid cells, CD5 is physically associated to the T- and B-cell
antigen-specific receptor (TCR and BCR, respectively) [9], and it
is therefore well positioned to modulate the intensity of antigen-
driven lymphocyte activation and differentiation signals.
Indeed, CD5 possesses a relatively large cytoplasmic domain
devoid of enzymatic activity but harboring potential tyrosine and
serine/threonine phosphorylation motifs compatible with a
function in signal transduction [10,11]. Engagement of CD5
may, however, result in different modulatory signals depending on
the cell type analyzed and the maturation stage [12]. In mature T
cells, CD5 was first considered as a co-stimulatory molecule for
TCR receptor signaling [13,14], but later studies showed a role for
this molecule as a negative regulator of TCR signaling in
thymocytes [15] and BCR signaling in B1a cells [16]. The fact
that negative regulation does not occur in the absence of the CD5
cytoplasmic domain suggests that this effect depends on intracel-
lular interactions mediated through signaling effector molecules
[17]. It should be noted here that although several candidates have
been proposed (CD72, gp35-40, IgVH, gp150, and CD5 itself), no
CD5 ligand has been independently verified to date [3].
Although CD5 is a transmembrane molecule, a soluble form of
human CD5 (shCD5) can be generated in activated T lympho-
cytes as a result of proteolytic cleavage [18]. Low levels of shCD5
(in the pico/nanomolar range) have been identified in the serum of
healthy individuals, with discrete increased expression of this form
reported in some autoimmune disorders such as rheumatoid
arthritis [19], primary Sjo¨gren’s syndrome [20] and atopic
dermatitis [21]. The functional relevance of sCD5 has not yet
been elucidated; however, the fact that elevated levels of this
protein have been found in certain autoimmune diseases suggests
that sCD5 may be an indicator of chronic or exacerbated T cell
activation, or alternatively, that it may play a role in the
modulation of the immune response by interacting with the still
uncharacterized endogenous CD5 ligand/s. Accordingly, affinity-
purified shCD5 from pooled human sera was shown to bind a
panel of different cell types of lymphoid (T and B), myeloid and
epithelial origin. This cell binding pattern was identical to that
obtained with a recombinant human sCD5 (rshCD5) molecule
produced in a mammalian cell expression system and co-
precipitating a new CD5L with a relative molecular mass of
150 kD [18]. Interestingly, rshCD5 induced a dose-dependent
inhibition of polyclonal T-cell lympho-proliferative responses
mediated by CD3, but not by phytohemagglutinin A (PHA) [22].
More recently it has been reported that both soluble and
membrane-bound human CD5 molecules bind and sense the
presence of pathogen-associated molecular patterns (PAMPs) of
fungal origin (namely, beta-glucans) [23]. This pattern-recognition
receptor (PRR) function is shared with a selected group of SRCR-
SF members and has been hypothesized to be involved in both
prevention of autoimmune phenomena and optimization of anti-
microbial effector T cell responses during microbial aggression
[24].
In an attempt to investigate the role of sCD5 in the homeostasis
of immune cell populations, as well as during the course of the
immune response, we generated a transgenic mouse line
expressing a soluble form of human CD5 under the transcriptional
control of the SV40 promoter and the immunoglobulin m heavy
chain enhancer (shCD5EmTg mice). Our assumption was that
shCD5 would work as a decoy receptor, which would likely block
the interactions between CD5 and its ligand/s (CD5L) whatever
they are and wherever they are expressed. This is possible because
we have observed cross-reactivity between human CD5 and
murine CD5L, as has also been described for the highly
homologous receptor CD6 [18]. Therefore, the study of these
mice might shed light on the consequences of this interaction and,
since the effects of the human protein can be tested, might serve as
a test bed for future clinical use of shCD5. A similar approach has
already been used for the study of other molecules, such as CTLA-
4 [25] and VEGF-3 [26]. It is shown here that shCD5EmTg mice
exhibit alterations in lymphocyte subpopulations with a regulato-
ry/suppressive function, which can be reproduced in normal non-
transgenic mice after repeated administration of exogenous
rshCD5. Moreover, the expression of circulating shCD5 appears
to be immunologically relevant, since shCD5EmTg mice showed
increased severity of experimentally induced autoimmune disor-
ders, and slower tumor growth compared with non-transgenic
littermates. The latter anti-tumoral effects were also reproduced by
repeated administration of purified rshCD5 to non-transgenic
mice. Therefore, our data support a role for CD5/CD5L
interactions in the homeostasis of some lymphocyte populations
with regulatory and/or effector function, while highlighting the
potential use of targeting CD5 as an immunomodulatory strategy
in cancer therapy.
Materials and Methods
Animals
In vivo studies were carried out under protocols approved by the
Ethics Committee for Animal Research of the University of
Barcelona (permits number 498/12, 505/12 and 507/12), and
were carried out in compliance with the International League of
Associations for Rheumatology Guide for the Care and Use of
Laboratory Animals, University of Cantabria, and the National
Institutes of Health and University of Alabama at Birmingham
Institutional Animal Care and Use Committee guidelines. All
efforts were made to minimize animal suffering.
Generation and genotyping of shCD5EmTg mice
The DNA sequence coding for the whole extracellular region of
CD5 was amplified from the pHbAPRI-neo-CD5.P346stop con-
struct [18] and subcloned into XhoI-ApaI restricted pIgHSV40s
vector which contained the SV40 promoter and the immunoglob-
ulin m heavy chain enhancer (Em). This vector, termed
pIgHSV40shCD5, was injected into fertilized eggs from a
CBAxC57Bl/6 mixed background. Founder mice were back-
crossed for 10 generations into the C57Bl/6 background. Non-
transgenic littermates were used in all experiments. Transgenic
mice were identified by PCR analysis of genomic DNA samples
from ear punch specimens in a GeneAmp PCR System 2700
termocycler (Applied Biosystems, USA). The cycling conditions
were: 30 cycles of 5 min at 94uC, 1 min at 92uC, 1 min at 53uC,
and 8 min at 72uC. The primers to detect the transgene were
specific for the extracellular region of human CD5 (forward, 59-
GCTGTCCCAGTGCCACGAACTT-39; reverse, 59-
GAAGCTCCTCTGTGTCCTCAT-39). Internal control ampli-
fication primers (forward, 59-TCACTCAAGG-
CAACCTTCCTGC-39; reverse, 59-CGACCTCATCTCTAAC-
CATGAACAG-39) specific for the invariant chain Ii of MHC class
II (LIEX) were also included. The resulting PCR products (450
and 150 bp, respectively) were separated in a 2% agarose gel and
visualized in a G:Box system (SynGene, UK).
Production, purification and labeling of recombinant
human proteins and mouse antibodies
The generation of expression constructs for recombinant soluble
human CD5 and CD6 as well as their production and purification
have been previously described [27,28].
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Mouse monoclonal antibodies (mAb) to human CD5, Cris-1
and Leu-1, were obtained from Dr. Ramon Vilella (Hospital
Clı´nic of Barcelona) and the American Type Culture Collection
(Manassas, VA), respectively, and purified by affinity chromatog-
raphy using HiTrap Protein G columns (GE Healthcare).
Biotinylation of recombinant proteins and mAbs was performed
with EZ-Link PEO-maleimide–activated biotin (Pierce) following
the manufacturer’s instructions.
ELISA assays
The circulating levels of shCD5 were quantified by sandwich
ELISA. 96-well plates (Nunc Maxisorb, Denmark) were coated
overnight (o/n) at 4uC with 2 mg/mL of Cris-1 mAb as capture
antibody, and then blocked for 1 h at 37uC with 2% bovine
seroalbumin (BSA) in phosphate buffered saline (PBS). Neat mouse
serum samples (100 mL) or serial dilutions of purified rshCD5,
used as protein standard, were added to wells and incubated for
2 h at room temperature (RT). After washing three times with PBS
0.05% Tween 20 (PBS-T), 100 mL of 2 mg/mL of biotin-labeled
Leu-1 mAb were added and incubated for 1 h at RT. Plates were
washed again three times with PBS-T and incubated with
horseradish peroxidase (HRP)-labeled streptavidin (Roche) for
30 min at RT. Color was developed in the plate using the ELISA
Amplification System (Invitrogen, UK) and absorbance measured
at 495 nm.
For detection of anti-human CD5 and CD6 mouse antibodies,
ELISA plates were coated o/n at 4uC with 2 mg/mL of rshCD5 or
rshCD6, respectively. After blocking with BSA, serially diluted
mouse serum samples (100 mL) were added to the wells and
incubated for 2 h at RT. After extensive washing with PBS-T,
wells were incubated for 30 min at RT with HRP-labeled anti-
mouse immunoglobulin antiserum (Sigma). Color was developed
in the plate by addition of TMB substrate (BD Biosciences, USA)
and absorbance measured at 450 nm.
Levels of TNP-specific antibodies of different isotypes were
determined by using ELISA plates coated o/n with TNP18-BSA
(3 mg/mL) in PBS. Once blocked with BSA, diluted 100 mL serum
samples (1/500 for detection of IgM, and 1/10000 for all IgG
isotypes) were added to the wells and incubated for 1 h at RT.
Then, biotinylated sheep anti-mouse IgM, IgG1, IgG2a, IgG2b,
IgG2c and IgG3 antisera (Jackson ImmunoResearch Laboratories,
USA) were incubated for 1 h at RT. After three washes with PBS-
T, HRP-labeled streptavidin was added and the plates developed
with TMB.
Immunoprecipitation and Western blot analysis of serum
shCD5
Pooled sera from shCD5EmTg mice and non-transgenic
littermates were sequentially precipitated to a final saturation of
20 and 70% ammonium sulfate. After extensive dialysis against
PBS, the 70% protein precipitate was immunoprecipitated with
Cris-1 mAb coupled CNBr-activated Sepharose (GE Healthcare)
beads [18,29]. Immunoprecipitates were separated on 10%
agarose gels under non-reducing conditions and then Western
blotted with biotin-labeled Leu-1 mAb and HRP-labeled strepta-
vidin. Membranes were developed by chemiluminescence (ECL,
Amersham Pharmacia).
Immunization of mice with T-dependent (TD) and -
independent (TI) antigens
To study the antibody response to TD and TI antigens, 7–8
week-old shCD5EmTg and non-transgenic littermates were used
and immunized i.p. under different experimental conditions. For
induction of anti-human CD5 and CD6 antibody responses, mice
were primed with 25 mg of rshCD5 or rshCD6, in complete
Freund’s adjuvant (CFA, Sigma-Aldrich, UK) and boosted three
weeks later with the same amount of protein in incomplete
Freund’s adjuvant (IFA). Two weeks after the boosting mice were
bled and their sera analyzed by ELISA using rshCD5 or rshCD6
as the coating antigen (see above).
For induction of anti-trinitrophenyl (TNP) antibodies mice were
given 50 mg of TNP5-KLH (as TD antigen) in 400 ml of PBS in
CFA at day 0 and with vehicle (PBS) at day 14, TNP0.3-LPS (as
type 1 TI antigen) or TNP65-Ficoll (as type 2 TI antigen) in 400 ml
PBS. Antigen-conjugated TNP haptens were provided by
Biosearch Technologies, Inc. (USA). Sera from immunized mice
were collected at days 0, 7 and 14 (for TI response) or 0, 7, 14 and
21 (for TD response) days after the primary immunization and
stored at 220uC until analysis.
Flow cytometry analysis of mouse lymphocyte
subpopulations
The following mAb were used to characterize lymphocyte
subpopulations in mice: Fluorescein isothiocyanate (FITC)-labeled
anti-mouse CD4 (eBioscience, US), B220 (eBioscience), BP-1
(eBioscience), IgD (eBioscience), CD21 (7G6, eBioscience) and
CD62L (Tonbo Biosciences); Phycoerythrin (PE)-labeled anti-
mouse CD23 (eBioscience), CD3cd (eBioscience), B220
(eBioscience), NK1.1 (eBioscience), CD5 (eBioscience), CD43
(BD Biosciences), CD11b (M1/70, eBioscience), CD93 (AA 4.1),
IgD (eBioscience), CD4 (L3T4), CD44 (BD Biosciences); PerCP-
Cy5.5-labeled anti-mouse CD25 (BD Biosciences), CD5 (BioLe-
gend) and CD19 (eBioscience); Allophycocyanin (APC)-labeled
anti-mouse CD24 (M1/69), CD3e (eBioscience), IgM (eBioscience)
and CD25 (eBioscience); AlexaFluor 680-labeled anti-mouse IgM
(eBioscience); AlexaFluor700 labeled anti-mouse CD8 (53-6.7);
APC-eFluor 780-labeled anti-mouse B220 (BioLegend); anti-
mouse IL-10 (JES5-16E3); Pacific blue-labeled anti-mouse B220
(BioLegend), GR1 (BD Biosciences) and CD11b (M1/70).
For staining, cell suspensions from spleen, lymph node and
thymus were obtained using a cell strainer (50 mm). Splenocytes
were depleted of erythrocytes by lysis with NH4Cl. Mouse
peritoneal cells were obtained from peritoneal lavage with 4 mL
PBS supplemented with 2% FCS and 0.01% sodium azide. Before
surface staining with predetermined optimal concentrations of
each mAb, cell samples (16106) were blocked by incubation with
anti-CD16/32 2.4G2 mAb (Mouse BD Fc Block) for 30 min at
4uC.
For IL-10 intracellular staining, cells were stimulated with
50 ng/ml PMA, 500 ng/ml ionomycin (Sigma-Aldrich) and LPS
(10 mg/ml, Escherichia coli serotype 0111:B4; Sigma-Aldrich) in the
presence of Golgi-stop (monensin 2 mM; eBioscience) for 4 h at
37uC, in 96-well v-bottom plates. After surface staining with anti-
B220, anti-CD5 and anti-CD1d antibodies, cells were fixed and
permeabilized using a Cytofix/Cytoperm kit (BD Pharmingen),
according to the manufacturer’s instructions, and stained with PE-
conjugated mouse anti-IL-10 mAb.
For FoxP3 intracellular staining, cells were stained with the PE-
labeled anti-mouse/rat Treg Staining Kit (eBioscience), according
to the manufacturer’s instructions. Briefly, 16106 cells in
suspension were stained with anti-CD4 and anti-CD25 antibodies
and incubated with Fixation/Permeabilization Solution 18 h at
4uC. After this incubation, cells were washed twice with
Permeabilization Buffer and incubated with anti-FoxP3 (Clone
FJK-16s) 30 min. at 4uC.
Nine-color flow cytometry was performed on a BD FACSCanto
flow cytometer (Becton Dickinson, US). Each analysis shown
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represents 500,000 events within the live lymphocyte gate. Flow
cytometric profiles were analyzed using FlowJo software (Tree
Star, USA).
Collagen-induced arthritis (CIA) model
Type II bovine collagen (provided by Dr. M. Griffiths,
University of Utah, Salt Lake City, USA) was dissolved at a
concentration of 2 mg/mL in 0.05 M acetic acid and emulsified
with CFA containing 4 mg/mL Mycobacterium tuberculosis (Chon-
drex, USA). For the induction of CIA, 8- to 10-week-old female
non-transgenic and shCD5EmTg6(DBA _ B6)F1 hybrid mice
were immunized once at the base of the tail with 150 mg of
collagen II in a final volume of 150 ml. Clinical evaluation of
arthritis severity was performed as described [30]. For radiological
studies, mice were anesthetized by i.p. injection of a mixture
containing: 50 mg/kg ketamine (Ketolar; Parke-Davis), 200 mg/kg
atropine sulfate (Braun Medical, Spain), and 4 mg/kg diazepam
(Roche, Spain). X-ray pictures were obtained using a CCX Rx ray
source of 70 Kw with an exposure of 90 ms (Trophy Irix X-Ray
System; Kodak, Spain). The radiological signal was digitalized
with a Trophy RVG Digital Imagining system and analyzed using
the Trophy Windows software. The severity of CIA was quantified
radiologically with a graded scale according to the presence of five
different radiological lesions (soft tissue swelling, juxtaarticular
osteopenia due to alterations in bone density, joint space
narrowing or disappearance, marginal erosions, and periosteal
new bone formation). The extension of every individual lesion
(local: affecting one digit or one joint in the carpus; diffuse:
affecting two or more digits and/or two or more joints in the
carpus) was graded from 0 to 1 as follows: 0, absence; 1/2, local; 1,
diffuse. To clearly establish the radiological score in each paw,
plain radiographs were assessed using a magnifying glass. Then,
each paw was graded from 0 to 5, giving a maximum possible
score of 20 for each mouse.
Experimental autoimmune encephalomyelitis (EAE)
model
C57Bl/6 non-transgenic and shCD5EmTg mice were immu-
nized with a single s.c. injection of 150 mg of MOG35–55 peptide
(BioSynthesis, USA) emulsified in CFA (Difco, supplemented with
400 mg/mL of Mycobacterium tuberculosis) on day 0, followed by
one i.p. injection of 200 ng pertussis toxin (LIST Biologicals, USA)
on day 0 and another on day 2 [31]. EAE symptoms were
monitored daily for 30–35 days using a standard clinical score
according to the following criteria: 0, no disease; 1, decreased tail
tone; 2, hindlimb weakness or partial paralysis; 3, complete
hindlimb paralysis; 4, forelimb and hindlimb paralysis; 5,
moribund state [32]. Animals with a clinical score ,2 as defined
by loss of tail tone were considered free of clinical disease.
For histology, mouse brains were snap frozen and sectioned
(10 mm) at peak disease scores, determined empirically for each
mouse as the fifth day after initial disease signs (score .0). Tissue
was stained with hematoxylin and eosin to detect CNS inflam-
matory infiltrates, or solochrome cyanin to assess myelination.
In vivo tumor growth assays
For tumor studies, B16 melanoma cells, which are of murine
C57Bl/6 origin, were used. For in vivo tumor growth, 56104 cells
were injected s.c. on the mid-dorsum with a 23-gauge needle.
Tumors were measured every other day with a Vernier calliper,
and the diameter in mm of the length and width of the tumors
averaged. Chemotherapy treatment, when used, was administered
at day 3 following tumor cell injection and consisted of a single
dose of 0.5 mg/kg vincristine and 3.3 mg/kg doxorubicin,
injected i.p. For experimental metastasis assays, 16105 cells were
injected i.v. After 15 days, mice were sacrificed, their lungs excised
and the number of metastases on the lung surface counted. For
both types of assays, results are expressed as mean 6 standard
error of mean (SEM).
Statistical analysis
Statistical significance of differences between result groups was
determined using Student’s t test, unless stated otherwise. In all
experiments, differences were considered statistically significant
when p was,0.05.
Results
Generation and characterization of shCD5EmTg mice
In an attempt to investigate the functional relevance of the
CD5/CD5L interactions in vivo, a new line of transgenic mice
(shCD5EmTg) was generated, which expresses a soluble form of
human CD5 (shCD5). This was done by taking advantage of
interspecies conservation of the receptor-ligand interactions
mediated by CD5, in a similar way to that reported for the highly
homologous receptor CD6 [33]. Accordingly, both biotin-labeled
shCD5 and shCD6 bound to activated human or mouse
lymphocytes to a similar extent, as illustrated by Figure S1.
The shCD5EmTg mice were engineered to express the whole
extracellular region of human CD5 (from initiation Met to Pro346)
under the transcriptional control of the SV40 promoter and the B-
cell specific Em enhancer (Fig. 1A). The transgene was injected
into fertilized eggs of CBAxC57Bl/6 mixed background and the
founder mice were backcrossed into the C57Bl/6 background.
Transgenic mice were identified with a specific PCR for the
extracellular region of human CD5 (Figure S2) and the
transgenic expression of shCD5 mouse serum was confirmed by
immunochemical studies. Thus, pooled sera from shCD5EmTg
mice or non-transgenic littermates were immunoprecipitated with
an anti-human CD5 mAb (Cris-1) and analyzed by Western
blotting with a second anti-human CD5 mAb (Leu-1). As
illustrated by Figure 1B, a 52-kDa band was detected in
shCD5EmTg mice sera, which was absent from that of non-
transgenic littermates. The serum levels of shCD5 expressed by
shCD5EmTg mice were further analyzed by sandwich ELISA and
were shown to be in the ,10–100 ng/mL range (Fig. 1C).
Further confirmation on the transgenic expression of shCD5
was obtained from the demonstration that shCD5EmTg mice were
tolerant to exogenously administered purified rshCD5, but not to
rshCD6. To evaluate this, the titers of anti-shCD5 or anti-shCD6
antibodies in shCD5EmTg mice immunized with two consecutive
doses (25 mg each) of either rshCD5 or rshCD6 were analyzed by
ELISA two weeks after the second immunization. As shown in
Figure 1D, sera from shCD5EmTg mice immunized with rshCD5
showed very low antibody levels against rshCD5, compared with
those of non-transgenic mice sera. The specificity of the anti-CD5
antibody response was demonstrated by the lack of detection of
antibodies reactive to both structurally similar (rshCD6) and
unrelated (BSA) proteins. In contrast, when immunized with
rshCD6 both shCD5EmTg mice and non-transgenic mice showed
similarly high and specific titers of anti-shCD6 antibodies, which
did not cross-react with related and unrelated protein controls
(Fig. 1E). This indicates that shCD5EmTg mice are tolerant to
human shCD5 but not to a highly homologous human protein
such as shCD6.
Immunomodulatory Effects of shCD5 Expression
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Figure 1. Generation and characterization of human soluble hCD5 transgenic mice (shCD5EmTg). A) Structure of the pIgHSV40shCD5
targeting vector. The cDNA sequence for shCD5 was inserted as XhoI-ApaI in between the promoter and polyA sequence of the pIg vector and then
isolated as ScaI-ApaLI fragment for oocyte injections. B) Western blot analysis of human CD5 immunoprecipitates from transgenic (shCD5EmTg) and
non-transgenic mice (NonTg) sera. The anti-CD5 Cris-1 mAb coupled with CNBr-activated Sepharose beads was used as immunoprecipitating agent.
Western blotting was then carried out using the Leu-1 mAb plus HRP-labeled anti-mouse Ig. As a positive control, purified rshCD5 (50 ng) was
included. C) ELISA detection of shCD5 in sera from shCD5EmTg mice. Sera from transgenic (shCD5EmTg, white) and non-transgenic littermates
(NonTg, black) mice were analyzed by sandwich ELISA using Cris-1 and biotin-labeled Leu-1 as capture and developing mAbs, respectively. A
standard rshCD5 curve was also analyzed in parallel to quantify results. D–E) shCD5EmTg mice are tolerant to exogenously administered rshCD5 but
not rshCD6. shCD5EmTg mice and wild-type littermates were immunized twice with rshCD5 (D) or rshCD6 (E) (25 mg) in Freund’s adjuvant (complete
and incomplete, sequentially) within a 3-week interval. Mouse sera were collected 2 weeks after the boosting and added to ELISA plates coated with
purified rshCD5, rshCD6 or BSA, then developed with a HRP-labeled anti-mouse IgG. Values represent the mean OD 450 nm values 6 SD obtained in
triplicate determinations for each sample (five mice per group). The total concentration of IgG was similar for both groups.
doi:10.1371/journal.pone.0084895.g001
Immunomodulatory Effects of shCD5 Expression
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e84895
shCD5EmTg mice exhibit normal proportions of major T
and B cell subpopulations and developmental stages
To investigate the phenotype of shCD5EmTg mice regarding
lymphocyte development and homeostasis, the total cell numbers
and percentages of major lymphocyte subpopulations were
analyzed in the thymus, lymph node, bone marrow, peritoneum
and spleen. As shown in Figure 2, total cell numbers were not
significantly different in the thymus, bone marrow or lymph node
of shCD5EmTg mice compared with non-transgenic littermates,
although the number of cells in peritoneum was significantly
higher in shCD5EmTg mice; this increase could not be ascribed to
any single population, as relative percentages of different cell
subpopulations remained unchanged (data not shown). A higher
number of cells was also observed in the spleen of shCD5EmTg
mice although this did not reach statistical significance.
Further analysis of major T cell subsets (CD4+ and CD8+) from
secondary lymphoid organs (lymph nodes and spleen) did not
detect any gross abnormalities in lymphocyte subpopulation
percentages of shCD5EmTg mice compared with non-transgenic
littermates (Fig. S3A and B). A similar scenario was observed in
thymus, where none of the different T cell developmental stages
(DN1–DN4, DP, SP CD4+, SP CD8+) appeared to be affected
(Fig. S3C and D).
B lymphocyte subsets from peripheral (spleen and peritoneum)
and central (bone marrow) organs were also analyzed. As shown in
Figure 3A, a significant decrease in the percentage of the
transitional 1 (T1, IgMhi IgDlo CD93/AA4+ CD232) and 2 (T2,
IgMhi IgDlo CD93/AA4+ CD23+) cells as well as an increase in
marginal zone B cells (MZB, IgMhi IgDlo CD93/AA4lo CD232)
were detected in the spleen of shCD5EmTg mice compared with
non-transgenic littermates. No significant differences were ob-
served between shCD5EmTg and non-transgenic mice regarding
the transitional 3 (T3, IgMlo IgDhi CD93/AA4+ CD21+), follicular
I (FOLI, IgMlo IgDhi CD93/AA4lo CD21+), follicular II (FOLII,
IgMhi IgDhi CD93/AA4+ CD21/35lo) and MZ precursor (MZP,
IgMhi IgDhi CD93/AA4+ CD21/35hi) cells (Figs. S4 and 5A). In
a similar way to what was observed with T cell development, we
did not find any major differences in B cell developmental stages in
the bone marrow (Pro/pre-B, early pro-B, pro-B and pre-B cells)
(Fig. S6).
However, as shown in Figure 3B and Figure S5B, analysis of
peritoneal B cells showed a significant decrease in the percentage
of B1a cells (B220+ IgMhi IgDlo CD5+) and a smaller, albeit
significant, increase in the percentage of B1b cells (B220+ IgMhi
IgDlo CD52). No differences were observed in mature B2 cells
(B220+ IgMhi IgDhi CD52).
Taken together, phenotypical analysis of shCD5EmTg mice
indicates that expression of shCD5 does not induce gross
alterations on T and B cell development, and that the only
abnormalities observed affect certain B cell subsets from spleen
(T1, T2, MZB) and peritoneum (B1a, B1b).
shCD5EmTg mice display reduced proportions of B and T
lymphocyte subsets with regulatory/suppressor function
Given that CD5+ B cells appeared to be reduced in
shCD5EmTg mice, a subset of IL-10 secreting B cells with a
regulatory/suppressor function, known as B10 cells (B220+
CD1dhi CD5+ IL10+) [34,35], was further analyzed. As shown
in Figure 4A and Figure S7A, B10 cells were significantly
decreased in both peritoneal lavage and spleen samples from
shCD5EmTg mice compared with non-transgenic littermates,
Figure 2. Analysis of total cell numbers in primary and secondary lymphoid organs from shCD5EmTg mice. Total number of
mononuclear cells in spleen, thymus, bone marrow, lymph node and peritoneal lavage samples was measured by flow cytometry using forward and
side scatter for gating. ** p = 0.0018.
doi:10.1371/journal.pone.0084895.g002
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suggesting that intact CD5-mediated interactions are needed for
the maintenance of this subpopulation.
It has recently been reported that CD5 expression regulates the
generation and/or function of T regulatory cells (Tregs) [7,36].
Since shCD5 might interfere with putative ligand binding of
endogenous CD5 expressed on T lymphocytes, we investigated
whether changes in Treg cell numbers could be detected in
primary and secondary lymphoid organs of shCD5EmTg mice. As
shown in Figure 4B and Figure S7B, no differences in the
percentage or number of Treg (CD4+ CD25+ FoxP3+) cells were
observed in the thymuses of shCD5EmTg mice. However, a
significant reduction in the percentage of Tregs was observed in
the lymph nodes of these mice compared with their non-transgenic
littermates.
NKT cells (NK1.1+ CD3+) constitute another CD5+ regulatory
cell subset. As shown in Figure 4C and Figure S7C, and
contrary to what was observed for B and T cell regulatory subsets,
NKT cells were found to be increased in spleens from
shCD5EmTg mice compared with non-transgenic littermates.
Overall, the data indicate that shCD5EmTg mice present
alterations in different regulatory cell subpopulations, which could
have important consequences for the immune response of these
mice.
To rule out random events of transgenesis and confirm that the
observed changes in regulatory cell subpopulations were caused by
increased circulating levels of shCD5, similar cell analyses were
performed on wild-type C57Bl/6 mice treated with repeated i.p.
infusions of purified rshCD5 protein (1,25 mg/kg, every other day
for two weeks). As shown in Figures 5A and 5B, B1a and B10
cells were significantly reduced in the peritoneum, but not in the
spleen of rshCD5-treated mice compared with control mice. In
addition, Treg cells were found to be reduced in the spleen but not
in the lymph nodes of wild-type mice injected with rshCD5
(Fig. 5C). Finally, analysis of NK1.1+ cells, showed an increase in
NKT cells (NK1.1+, CD3+) in the spleen of rshCD5-treated mice
(Fig. 5D). These data indicate that sustained treatment of wild-
type mice with exogenous rshCD5 can induce similar phenotypical
changes to those observed in shCD5EmTg mice, unequivocally
ascribing the effects of transgenesis to the presence of circulating
shCD5.
Figure 3. Flow cytometry analysis of B lymphocyte subpopulations in shCD5EmTg mice. A) To analyze peripheral B cell subsets from
spleens of shCD5 transgenic mice and non-transgenic littermates, we used a gating strategy adapted from Cariappa et al [45]. Gated on
IgMhighIgDlow, transitional 1 (T1), transitional 2 (T2) and marginal zone B cells can be distinguished based on their differential expression of the surface
markers CD23 and CD93/AA4. *** p#0.0003 * p = 0.0221. B) Cells obtained from peritoneal lavage samples were stained to distinguish B1a cells
(B220+IgMhighIgDlowCD5+), B1b cells (B220+IgMhighIgDlowCD52) and B2 cells (B220+IgMhighIgDhighCD52) in shCD5 transgenic mice and non-
transgenic littermates. * p = 0.0294 ** p = 0.0016.
doi:10.1371/journal.pone.0084895.g003
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Antibody response to T-independent-1 antigens is
enhanced in shCD5EmTg mice
To further evaluate the functional consequences of the
lymphocyte subset alterations observed in shCD5EmTg mice, in
vivo antibody responses to different T-dependent and –indepen-
dent antigens were analyzed. Transgenic shCD5EmTg mice and
non-transgenic littermates were immunized i.p. with the hapten
trinitrophenol (TNP) conjugated to a T-dependent (TD) antigen
(keyhole limpet hemocyanin; TNP5-KLH), a T-independent type
1 (TI-1) antigen (LPS; TNP0,3-LPS) and a T-independent type 2
(TI-2) antigen (Ficoll; TNP65-Ficoll), and serum levels of specific
anti-TNP antibodies analyzed by ELISA. No significant differ-
ences were observed for anti-TNP antibody levels in shCD5EmTg
mice immunized with TD antigen (TNP5-KLH), with the
exception of IgG1 antibodies at day 21 post-immunization, which
were significantly higher in transgenic mice (Fig. 6A and Fig.
S8A). However, a trend towards higher levels of IgM antibodies
was also observed in shCD5EmTg mice. Regarding the response to
the TI-1 antigen (TNP0,3-LPS), higher levels of anti-TNP
antibodies were also observed for shCD5 transgenic mice in all
the Ig isotypes tested, at nearly all time points (Fig. 6B and Fig.
S8B). By contrast, levels of antibodies in mice immunized with the
Figure 4. Flow cytometry analysis of T and B cells with regulatory phenotype in shCD5EmTg mice. A) Cells from peritoneal lavage and
spleen samples from shCD5EmTg mice and non-transgenic littermates were stained for the presence of Breg (B10) cells (B220+CD1d+CD5+IL10+). ***
p#0.0006 ** p = 0.0015. B) Lymph node and thymus cells were stained for the presence of Treg cells (CD4+CD25+ Foxp3+) in shCD5EmTg mice and in
non-transgenic littermates ** p = 0.0038. C) Spleen cells were stained to detect NKT cells (CD3+NK1.1+) in shCD5EmTg mice and non-transgenic
littermates. * p = 0.0406.
doi:10.1371/journal.pone.0084895.g004
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TI-2 antigen (TNP65-Ficoll) appeared to be unchanged in
shCD5EmTg mice at all time points, for all the different Ig
isotypes analyzed (Fig. 6C and Fig. S8C). These results suggest
that the B cell antibody response against TI-1 antigens – and, to a
lesser extent, against TD antigens – is enhanced in shCD5EmTg
mice compared with that of non-transgenic littermates.
Experimentally induced autoimmune diseases are more
severe in shCD5EmTg mice
To gain insight into the in vivo immune response to auto-
antigens in shCD5EmTg mice, two different models of experi-
mentally induced autoimmune disease were evaluated. First,
collagen-induced arthritis (CIA) in (B66DBA/1) F1 mice, a well-
established model of T-cell mediated autoimmune disease
resembling rheumatoid arthritis, was used. As shown in
Figure 7A and Figure S9A, increased severity of arthritis
symptoms (oedema, joint narrowing, marginal erosion, osteopenia)
was observed in shCD5EmTg mice compared with non-transgenic
littermates. Moreover, IL-6 levels were significantly increased in
joint tissue from shCD5EmTg mice compared with that of non-
transgenic mice, while a trend towards increased levels of other
pro-inflammatory cytokines (IFN-c, IL-1b, IL-17 and TNF-a) was
observed (Fig. 7B and Fig. S9B). Total anti-collagen II antibody
levels were also increased in the sera of shCD5EmTg mice, mostly
of the IgG2 subtype, (Fig. 7C and 7D and Fig. S9C),
characteristic of an enhanced Th1 response.
To further validate the results obtained with the CIA model, the
MOG-induced model of experimental autoimmune encephalo-
myelitis (EAE), a well-established model of T-cell mediated
autoimmune disease resembling multiple sclerosis, was evaluated.
As shown in Figure 7E, the clinical score of the disease was
significantly increased in shCD5EmTg mice compared with non-
transgenic littermates. Moreover, demyelination was also in-
creased in shCD5EmTg mice (Fig. 7F). Altogether, the data show
that shCD5EmTg mice display more severe forms of experimen-
tally induced autoimmune disease in models developed against
different auto-antigens.
Tumor growth is slowed in shCD5EmTg mice
Since autoimmune and anti-tumoral immune responses are
both directed mainly against self-antigens, the in vivo response of
shCD5EmTg mice to autologous tumor antigens was evaluated. A
melanoma B16 cell model (syngeneic with C57Bl/6 mice) was
chosen, and tumor growth was recorded over time. As shown in
Figure 8A, B16 tumors grew significantly more slowly in
shCD5EmTg mice compared with their non-transgenic littermates.
Taking these data into account, a potentially improved response of
shCD5EmTg mice to i.v. injected B16 cells was also evaluated.
Experimental metastasis assays revealed a decrease in the number
of lung metastases observed in shCD5EmTg compared with non-
transgenic littermates (Fig. 8B), which was close to significance
(p = 0.09).
To evaluate whether administration of exogenous rshCD5 to
non-transgenic mice could also delay tumor growth, wild-type
C57Bl/6 mice s.c. implanted with B16 cells were treated with
vehicle (PBS+glycerol) or rshCD5 (1,25 mg/kg) administered
Figure 5. Flow cytometry analysis of T and B cells with regulatory phenotype in wild-type C57Bl/6 mice treated with exogenous
rshCD5. A) B1a cells were analyzed as before in peritoneal lavage samples from wild-type C57Bl/6 mice treated with exogenous rshCD5 (25 mg every
48 hs for 14 days) or BSA as control. *** p = 0.0007. B) Cells from peritoneal lavage and spleen samples were stained for the presence of B10 cells in
wild-type C57Bl/6 mice treated with exogenous rshCD5 (25 mg every 48 hs for 14 days) or BSA as control. C) Lymph node and spleen cells were
stained for the presence of Treg cells in wild-type C57Bl/6 mice treated with exogenous rshCD5 (25 mg every 48 hs for 14 days) or BSA as control. *
p = 0.0156. D) Spleen cells were stained to detect NKT cells in wild-type C57Bl/6 mice treated with rshCD5 (25 mg i.p., every 48 hs for 14 days) or BSA
as control. *** p = 0.0004.
doi:10.1371/journal.pone.0084895.g005
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every 48 h from the day of tumor cell injection. A single dose of
chemotherapy (vincristine 0.5 mg/kg, doxorubicin 3.3 mg/kg)
was also administered at day 3 after tumor cell injection for both
groups. As shown in Figure 8C, tumor progression was slowed in
mice treated with chemotherapy plus rshCD5, compared with
mice treated with chemotherapy plus vehicle. Altogether, these
results suggest that increased circulating levels of shCD5 delay
progression of melanoma cells in mouse tumor models.
Discussion
Important immunomodulatory properties have been ascribed to
CD5 during lymphocyte development and activation [37], which
Figure 6. shCD5EmTg and non-transgenic mice response to immunization with T-dependent and T-independent (type 1 and type 2)
antigens. Mice were immunized i.p. with 50 mg TNP5-KLH (A), TNP0.3-LPS (B) or TNP65-Ficoll (C) prepared in 400 ml of PBS in complete Freund’s
adjuvant at day 0 and in 400 ml vehicle at day 14, as examples of TD, TI type 1 and TI type 2 antigens, respectively. Sera from immunized mice were
collected at days 0, 7 and 14 (for TI response) or 0, 7, 14 and 21 (for TD response) after the primary immunization and levels of TNP-specific antibodies
determined by ELISA. Ig levels are expressed as OD 450 nm values. The bars represent the average value for each group. ** p,0.05 *** p,0.01.
doi:10.1371/journal.pone.0084895.g006
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Figure 7. Exacerbated autoimmune disease in shCD5EmTg mice. A) Analysis of CIA induction in (DBA_B6)F16shCD5EmTg mice and non-
transgenic littermates. 7–8 week old mice were immunized s.c. near the base of the tail with 100 ml of antigen (2 mg/ml type II bovine collagen)
emulsified in CFA plus Arthrogen-CIA adjuvant. Radiological signs were scored weekly for each mouse and results for each group averaged to
determine overall clinical score. B) IL-6 levels were determined by real time RT-PCR in joint tissue, normalizing results to GAPDH expression levels.
Results are expressed in arbitrary units (A.U.). * p = 0.05. C) and D) Antibodies against type II collagen were measured by ELISA in the sera of
(DBA_B6)F16shCD5EmTg transgenic mice and non-transgenic littermates. Antibody determination included total IgG (C) and IgG1 (D). Results are
expressed as OD 450 nm. E) Analysis of EAE induction in shCD5EmTg and non-transgenic mice. 8–10 week old mice were administered s.c. with 200 ml
of antigen (50 mg MOG peptide) in CFA. At the time of immunization and 48 hs later, 200 ng of Pertussis toxin were also injected i.p. Clinical score
was determined daily and it represents the average value for each mice, where 0 = no disease; 0.5 = partially motionless tail; 1 = motionless tail;
2 = ataxia; 3 = loss of mobility in one limb; 4 = loss of mobility in back limbs; 5 = moribund. Graphs show the comparison between clinical scores of
shCD5EmTg (n = 5) and non-transgenic mice (n = 10). p = 0.05 (Two-way ANOVA test). F) Demyelination and infiltration scores, as detected by
solochrome cyanin and hematoxylin and eosin staining, respectively. ** p = 0.02.
doi:10.1371/journal.pone.0084895.g007
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make this receptor a potential target for immunotherapeutic
approaches. Although no CD5 deficiency has been reported in
humans, studies in CD52/2 mice have provided valuable
information in this regard, showing CD5 to act as a negative
modulator of antigen-driven activation of T cells (and certain B
cells) [15,16]. Considering that genetic deletion or silencing of
CD5 in humans would be fraught with both technical and ethical
problems, induction of sustained circulating levels of a soluble
form of CD5 was devised as an alternative strategy of hindering
this receptor in a functional and reversible way. In order to avoid
repeated infusions of expensive purified protein and also to
maintain stable levels of soluble CD5, a new shCD5-expressing
transgenic mouse line (shCD5EmTg) was generated, which may
serve as a test-bed for future applications in the clinic.
The shCD5EmTg mice herein reported display modest, albeit
readily detectable and sustainable serum levels of shCD5 from
early stages of development, making the mice tolerant to the
human protein. To develop this transgenic mouse line, advantage
was taken of the inter-species conservation of the receptor-ligand
interactions existing between mouse and human CD5, something
which had already been reported for the closely related receptor
CD6 [33,38]. Indeed, shCD5 is able to interact with the as yet
undefined CD5 ligand/s, thus likely acting as a decoy receptor
capable of impairing the functional consequences of receptor-
ligand interactions mediated by membrane-bound CD5. Thus,
shCD5EmTg mice would have a lower threshold for antigen-
specific receptor-mediated activation and subsequently, an en-
hanced immune response. This is confirmed in this work, where
shCD5EmTg mice are shown to have an increased response
against different types of antigens.
Transgenic shCD5EmTg mice were shown to display an
enhanced in vivo antibody response to certain soluble antigens,
particularly TD and TI-1 antigens. Indeed, induction of two
different experimental autoimmune diseases (CIA and EAE)
resulted in a more severe outcome for shCD5EmTg mice
compared with non-transgenic littermates. The increase in disease
severity was measured not only by clinical score, but also through
determination of pro-inflammatory cytokine levels and autoanti-
body responses. While no CIA studies have been carried out in
CD52/2 mice, it has been recently shown that CD52/2 and
CD5DCKIIBD mice (mice expressing a truncated and functionally
defective form of CD5) immunized with high doses of MOG show
more severe forms of EAE than wild-type mice [39]. Thus,
physical deletion and functional knock-down of CD5 both appear
to lead to a similar outcome with regard to autoimmune responses.
Both autoimmune and anti-tumor responses are directed mainly
towards autologous antigens. Indeed, syngeneic B16 melanoma
tumors developed in shCD5EmTg and in non-transgenic mice, but
grew at a slower rate in shCD5EmTg mice, which also showed a
decreased number of lung metastases following i.v. injection of
tumor cells. These results are also in agreement with previous
studies carried out in CD52/2 mice, in which B16F10 tumors
grew more slowly compared to those in wild-type mice [40].
Phenotypical analysis of shCD5EmTg mice did not reveal any
gross alterations in major lymphocyte subpopulations. However,
careful subpopulation analysis showed a decrease in T and B cell
subsets with regulatory function, as well as an increase in NKT
cells. It has been reported that generation of thymus-derived T
regulatory cells (nTregs) – which express high levels of membrane-
bound CD5 - appears to be regulated by CD5 expression [7,36].
In shCD5EmTg mice, Treg cells (CD4+CD25+FoxP3+) were
decreased in the periphery but not in the thymus. This could be
explained by the fact that shCD5 expression is under the control of
the Em enhancer and is thus expressed preferentially by B cells.
Local expression in the thymus would thus be very low and might
not be enough to alter the development or maintenance of nTreg
cells, suggesting that the observed decrease in Treg cells is at the
expense of inducible Treg (iTregs) cells. Another possibility is that
Figure 8. Delayed tumour growth in shCD5EmTg mice. A)
shCD5EmTg mice (n = 16) and non-transgenic littermates (n = 15) were
injected s.c. with 56104 B16 melanoma cells. Tumour growth was
recorded over time by measuring with a Vernier calliper. *** p = 0.0177.
B) Experimental metastasis assay. Mice were injected i.v. with 16105 B16
melanoma cells. Fifteen days later, mice were sacrificed, their lungs
removed and the metastases on the surface counted. p = 0.0994. C)
Non-transgenic C57Bl/6 mice (n = 5 for each group) were injected with
B16 cells as before. Chemotherapy (vincristine 0.5 mg/kg, Doxorubicin
3.3 mg/kg) was administered i.p. at day 3 after tumor cell injection.
Additionally, rshCD5 (25 mg) or vehicle was injected i.p. every 48 hs for
the duration of the experiment (20 days). ** p = 0.0083.
doi:10.1371/journal.pone.0084895.g008
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cross-linking of membrane-bound CD5 is not necessary for T cell
development in the thymus, as it has been reported that the
cytoplasmic region alone might be sufficient for intrathymic
selection [41]; this is consistent with the authors mentioning the
lack of CD5L expression in the thymus. However, the authors also
point out that CD5-CD5L interactions would indeed be important
in the periphery, which is in agreement with our results. Thus,
although the extracellular region of CD5 might be dispensable for
some of its functions, it is still necessary for modulation of antigen-
specific receptor signalling, at least in the periphery.
B10 cells were also decreased in shCD5EmTg mice. The same
subpopulation is also decreased in CD52/2 and in
CD5DCKIIBD mice (data not shown), supporting an important
role for intact CD5 function in the maintenance of this
subpopulation [42]. Indeed, it has been reported that CD5
expression is required for IL-10 production by Bregs, acting as a
survival factor [42]. In a similar way, intact CD5 function might
be required for other CD5-expressing cell types, such as NKT
cells. It is also possible that NKT cell number and/or activity
could be influenced indirectly by regulatory T and/or B cells, as
has been speculated previously [43].
Importantly, the observed changes in regulatory lymphocyte
subpopulations were not due to random transgene insertion, since
the phenotype could be reproduced in wild-type C57Bl/6 mice by
repeated administration of exogenous rshCD5 protein. These
results indicate that there is a causal relationship between the
presence of increased circulating levels of shCD5 and changes in
cell subpopulation dynamics, particularly in those cell types with
high membrane-bound CD5 expression.
The results obtained in functional assays (autoimmunity and
tumor models) tie in well with the decrease in lymphocyte
subpopulations with regulatory/suppressor function observed in
shCD5EmTg mice. Regulatory cells have been shown to suppress
activation of the immune system, and a decrease in these cells
would then be expected to enhance the immune response to self
and non-self antigens, particularly when coupled with an increase
in NKT cells. The latter cells are able to generate large quantities
of cytokines that can quickly modulate and polarize the immune
response. However, a decrease in Treg cells by itself has been
reported to slow down tumor growth [44].
Although the main intention of these experiments was to
characterize the immune response in shCD5EmTg mice, these
mice were also developed to test potential future clinical
applications of shCD5. As such, our results suggest a beneficial
effect of shCD5 in the treatment of tumors, through an
enhancement in the in vivo anti-tumor response. Cancer treatment,
however, is usually a combination of different drugs and/or
therapies; if shCD5 were ever to be used in the treatment of
tumors, it would probably be as an adjuvant to an established
therapy such as chemotherapy. Our results show that exogenous
repeated administration of rshCD5 in combination with chemo-
therapy improved the performance of chemotherapy alone in
mice, suggesting that this protein might be used as an adjuvant of
standard chemotherapy.
In conclusion, impairment of CD5/CD5L interactions by
shCD5 results in an enhancement of the immune response against
autologous antigens. This enhancement could be due to the
observed changes in lymphocyte subpopulations with regulatory
function; another possibility is that, considering that CD5 is a
negative regulator of T and B cell responses, impairment of its
function could also result in enhanced activation of effector T and
B cells. Although it is not clear which mechanism is prevalent, it is
likely that both effects contribute to the overall phenotype in a
combined manner. The results therefore suggest that shCD5 is an
immunomodulatory target that could be used in the treatment of
diseases which would benefit from an enhancement of a normal or
depressed immune response, such as cancer.
Supporting Information
Figure S1 Interespecies cross-reactivity of receptor-
ligand interactions mediated by CD5 and CD6. Mouse
(top panels) and human (bottom panels) PBMCs (1.56105) were
cultured for 72 hs in the presence (bold line) or absence (fine line,
gray filling) of PMA 100 ng/ml and Ionomycin 1 mg/ml. Cells
were then incubated with 1 mg biotin-labeled shCD5 (left panels)
or shCD6 (right panels) for 1 hr, and developed with FITC-
conjugated streptavidin for further analysis by flow cytometry.
Results shown correspond to the gated lymphocyte subpopulation.
(TIF)
Figure S2 Identification of shCD5EmTg mice by PCR.
Following PCR amplification of shCD5 from tail DNA, a PCR
product of the expected size (450 bp) was detected in transgenic
mice. A fragment of 150 bp corresponding to the LIEX gene was
also amplified as an internal control for the PCR.
(TIF)
Figure S3 Analysis of major T lymphocyte subpopula-
tions and development in shCD5EmTg mice. Lymph node
(A) and spleen (B) cells were stained with anti-CD4 and anti-CD8
specific antibodies to identify CD42, CD82, or CD42CD82
(mostly B cells). C) To analyze the effect of shCD5 expression on T
cell development, thymocytes were stained with anti-CD4 and
anti-CD8 antibodies to identify DN, DP, CD4+SP and CD8+SP
cells. D) To analyze the effect of shCD5 expression on early T cell
development, thymocytes were stained with anti-CD44 and anti-
CD25 antibodies to distinguish between DN1 (CD44+CD252),
DN2 (CD44+CD25+), DN3 (CD442CD25+) and DN4
(CD442CD252) cells.
(TIF)
Figure S4 Flow cytometry analysis of B lymphocyte
subpopulations in shCD5EmTg mice. To analyze peripheral
B cell subsets from spleen and peritoneum, we used a gating
strategy adapted from Cariappa et al [45]. Transitional 3 (T3) and
follicular I (FOLI) cells can be distinguished in the IgMlowIgDhigh
gated subpopulation using the CD21/35 and CD93/AA4
markers. Finally, the IgMhighIgDhigh gated subpopulation allows
for the detection of follicular II (FOLII) cells and marginal zone
precursors (MZP) based on the surface expression of AA4 and
CD21.
(TIF)
Figure S5 Gating for flow cytometry analysis of B
lymphocyte subpopulations in shCD5EmTg mice. A)
Representative dot plots showing the gating strategy for B cell
supopulation analysis. First, cells were gated for IgM and IgD;
subsequently, T1, T2 and MZ cells were detected in the
IgMhighIgDlow gate by staining with CD93/AA4 and CD93.
Similarly, gated on IgMlowIgDhigh, FOL I and T3 cells could be
distinguished according to CD21 and CD93/AA4 staining.
Finally, gating on IgMhighIgDhigh allowed for detection of FOL
II and MZP based on CD93/AA4 and CD21/35 staining. B)
Representative dot plots showing the gating strategy for B1 and B2
subpopulation analysis. Gated on IgMhighIgDlow, B1a and B1b
cells can be distinguished based on their CD5 expression, while B2
cells are IgMhighIgDhigh.
(TIF)
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Figure S6 Analysis of B lymphocyte development in
shCD5EmTg mice. To analyze the effect of shCD5 in B
lymphocyte development, bone marrow cells were stained with a
series of antibodies (CD43, B220, CD24 and BP-1) to identify the
different B cell subsets at various stages of maturation. From the
gated CD43+B220+ subpopulation, pre-pro-B cells (CD24lowBP-
12), early pro-B cells (CD24+BP-12), late pro-B cells (CD24+BP-
1+) and pre-B cells (CD24highBP-1+) could be identified based on
the expression of CD24 and BP-1.
(TIF)
Figure S7 Gating for flow cytometry analysis of regula-
tory lymphocyte subpopulations in shCD5EmTg mice. A)
Representative dot plots showing the gating strategy for B10 cell
analysis. Cells gated on CD1d+CD5+ were analyzed for B220 and
IL-10 staining; B220+IL-10+ cells were considered as B10 cells. B)
Representative dot plots showing the gating strategy for Treg cell
analysis. Gated on CD4+, CD25+FoxP3+ cells were considered as
Treg cells. C) Representative dot plots showing the gating strategy
for NKT cell analysis. CD3+NK1.1+ cells were considered as
NKT cells.
(TIF)
Figure S8 shCD5EmTg and non-transgenic mice IgM
response to immunization with T-dependent and T-
independent (type 1 and type 2) antigens. Mice were
immunized i.p. with 50 mg TNP5-KLH (A), TNP0.3-LPS (B) or
TNP65-Ficoll (C) in 200 ml PBS, as examples of TD, TI type 1 and
TI type 2 antigens, respectively. Sera from immunized mice were
collected at days 0, 7 and 14 (for TI response) or 0, 7, 14 and 21
(for TD response) after the primary immunization and levels of
TNP-specific antibodies determined by ELISA. IgM levels are
expressed as OD 450 nm values. The bars represent the average
value for each group. ** p,0,05.
(TIF)
Figure S9 Exacerbated autoimmune disease in
shCD5EmTg mice. A) Radiological signs (edema, joint narrow-
ing, marginal erosions and osteopenia) were scored at week 8 for
each mouse as described in the Materials and Methods section. B)
Cytokine mRNA levels were determined by real time RT-PCR in
joint tissue, normalizing results to GAPDH expression levels.
Results are expressed in arbitrary units (A.U.). C) IgG1 antibodies
against type II collagen were measured by ELISA in the sera of
(DBA_B6)F16shCD5EmTg transgenic mice and non-transgenic
littermates at weeks 0 and 8. Results are expressed as OD 450 nm.
(TIF)
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